In persistent or recurring infections, the problem is not only the presence of the microorganism but also the way it manages to survive within the body.
Biofilm represents a fundamental protection strategy for many bacteria and yeasts. As long as this structure remains intact, even correct therapies may be only partially effective.
For this reason, in recent years, research focus has shifted toward approaches capable of acting not only on the microorganism but also on the structure that protects it.
Indice
Why biofilm is a therapeutic target
The biofilm is a protective structure produced by bacteria and released externally; it thus appears as an extracellular matrix that encloses and protects them.
This matrix is mainly composed of:
- polysaccharides
- proteins
- extracellular DNA
The presence of protein components makes the biofilm particularly stable and resistant to the action of external agents.
Acting on the protein component of the biofilm therefore represents one of the strategies to undermine its overall structure.
What are proteolytic enzymes
Proteolytic enzymes are molecules capable of degrading proteins, breaking them down into simpler components.
In the biological field, these types of enzymes are involved in numerous physiological processes. In relation to biofilm, the interest lies in the possibility of intervening on the protein components of the extracellular matrix.
Reducing the integrity of the matrix can make the biofilm less compact and more vulnerable.
Proteolytic enzymes and biofilm: the scientific rationale
From a scientific perspective, the use of proteolytic enzymes is based on a key principle: weakening the structure of the biofilm to reduce the protection of microorganisms.
When the extracellular matrix is partially broken down:
- bacteria are less protected
- the permeability of the biofilm increases
- the risk of infection persistence can be reduced
This approach does not replace traditional therapies but acts as a complementary strategy in contexts where biofilm plays a central role.
Patented enzymatic blend
A specific blend of proteolytic enzymes consisting of Bromelain, extracted from the pineapple stem, Papain, derived from papaya, and Fungal Protease extracted from the Aspergillus oryzae fungus, was developed to act on the structure of the biofilm.
The formulation has been patented and was evaluated through an in vitro study that analyzed its activity on Escherichia coli biofilm.
The results showed the enzymatic blend’s ability to limit biofilm formation and break down its matrix, confirming the rationale of the enzymatic approach.
Quando considerare un approccio mirato al biofilm
An intervention that takes into account the biofilm can be particularly relevant in the presence of:
- recurrent cystitis
- bacterial prostatitis
- persistent urinary tract infections
- disorders that improve only temporarily after therapy
In these contexts, the biofilm can represent one of the factors contributing to the chronicization of the problem.
A shift in perspective for managing persistent infections
Addressing the biofilm means going beyond the management of a single infectious episode and considering the mechanisms that allow microorganisms to survive over time.
The enzymatic approach represents one of the most studied strategies for intervening on the protective structure of the biofilm, opening new possibilities in the management of recurrent infections.